| 000 | 01731 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513120218.0 | ||
| 264 | 0 | _c19970623 | |
| 008 | 199706s 0 0 eng d | ||
| 022 | _a0039-2499 | ||
| 024 | 7 |
_a10.1161/01.str.28.5.1015 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMorocutti, C | |
| 245 | 0 | 0 |
_aIndobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. _h[electronic resource] |
| 260 |
_bStroke _cMay 1997 |
||
| 300 |
_a1015-21 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnticoagulants _xadverse effects |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xdrug therapy |
| 650 | 0 | 4 |
_aCyclooxygenase Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIsoindoles |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPhenylbutyrates _xadverse effects |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Diseases _xprevention & control |
| 650 | 0 | 4 |
_aWarfarin _xadverse effects |
| 700 | 1 | _aAmabile, G | |
| 700 | 1 | _aFattapposta, F | |
| 700 | 1 | _aNicolosi, A | |
| 700 | 1 | _aMatteoli, S | |
| 700 | 1 | _aTrappolini, M | |
| 700 | 1 | _aCataldo, G | |
| 700 | 1 | _aMilanesi, G | |
| 700 | 1 | _aLavezzari, M | |
| 700 | 1 | _aPamparana, F | |
| 700 | 1 | _aCoccheri, S | |
| 773 | 0 |
_tStroke _gvol. 28 _gno. 5 _gp. 1015-21 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/01.str.28.5.1015 _zAvailable from publisher's website |
| 999 |
_c9139891 _d9139891 |
||